We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab (Imdylltra) to treat adult patients with small cell lung cancer (SCLC) that has spread throughout the lungs and/or to other parts of the...
FCDO travel advice for Turkmenistan. Includes safety and security, insurance, entry requirements and legal differences.
Before you travel No travel can be guaranteed safe. Read all the advice in…
This information is for people travelling on a full ‘British citizen’…
Terrorism There is a high threat of terrorist attack globally affecting UK…
Before you travel check that: your destination can provide the healthcare…
The Foreign, Commonwealth & Development Office (FCDO) cannot provide…
The CMA investigated the anticipated acquisition by Theramex HQ UK Limited of the European Rights to Viatris’ Femoston and Duphaston Products.
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine aprocitentan (Jeraygo) to treat hypertension (high blood pressure) in adults whose blood pressure cannot be adequately controlled by at least three other medicines (also known as resistant hypertension).
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept (Winrevair) to treat pulmonary arterial hypertension (PAH).
Following its Phase 1 investigation, the CMA has found that Theramex's proposed purchase of Femoston and Duphaston could reduce competition and choice for hormone replacement therapy treatments.
Form TASR221: Response to Application for Direction for Succession Tenancy on Retirement.
Use this form to apply to rectify the register for registered trade marks only
This note is part of the statutory guidance under s215 of the HRA 2008 (from 1 April 2024)
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).